ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ

ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ, ΤΟΜΟΣ 72, TEYXOΣ 1−3, 2010 8112. Nicholson et al: EGFR and cancer prognosis. Eur J Can−cer 2001;37S: Suppl 4:9−15.13. Yang XD et al: Developement of ABX−EGF, a fully hu−man anti−EGF receptor monoclonal antibody, for can−cer therapy. Crit Rev Oncol Hematol 2001;38(1):17.14. Cox AD, Der CJ. Ras family signaling: therapeutic tar−geting. Cancer Biol Ther 2002;1:599.15. Lievre A mutations as an independent prognostic factorin patients with advanced colorectal cancer treatedwith cetuximab. J Clin Oncol 2008; 26:374−379.16. Baldus et al: Pravalence and heterogeneity of KRAS,BRAF and PIC3CA mutations in primary colorectal ad−enocarcinomas and their corresponding metastases.Clinical Cancer Research 2010; 16:790−799.17. Amado IG et al. Wild type KRAS is required for pani−tunumab efficacy in patients with metastatic colorectalcancer. J Clin Oncol 2008; 26: 1626−1634.18. Tsutsui S et al: Prognostic value of cerb−B2 expressionin breast cancer. J Surg Oncol 2002;79(4):216−223.19. Piccart MJ et al: HER2: a “predictive factor” ready touse in the daily management of breast cancer patients?Eur J Cancer 2000;36:1755−1761.20. Slamon DJ et al: Use of chemotherapy plus a monoclo−nal antibody against HER2 for metastatic breast cancerthat overexpresses HER2 N Engl J Med 2001;344:783−792.21. Piccart MJ et al: Trastuzumab after adjuvant Chemo−therapy in HER2 – positive breast cancer. N Engl J Med2005;353:1659−1672.22. Geyer CE et al: Lapatinib plus capecitabine for HER−2 positive advanced breast cancer N Engl J Med2006;355:2733−2743.23. Early breast cancer trialists Collaborative group. Multi−agent chemotherapy for early breast cancer. CochraneDatabase Syst Rev. 2002.24. Dhesy−Thind B et al: Her−2/neu in systemic therapy forwomen with breast cancer: a systemic review. BrestCancer Res Treat. 2008;109:209−229.25. Gennari A et al: Her−2 status and efficacy of adjuvantanthracyclines in early breast cancer: a pooled analysisof randomized trials. J Natl Cancer Inst. 2008;100:14−20.26. Jaervinen TA et al: Amplification and deletion oftopoisomerase II alpha associate with ErbB−2 ampli−fication and affect sensitivity to the topoisomerase IIinhibitor doxorubicin in breast cancer. Am J Pathol.2000;156:839−847.27. Di Leo A et al: Anthracyclines: the first generation ofcytotoxic targeted agents? A possible dream. J ClinOncol 2008;26:5011−5013.28. Makrides V et al: Evidence for two distinct bindingsites for tau on microtubules. Proc Natl Acad Sci USA.2004;101:6746−51.29. Rouzier R et al: Microtubule associated protein tau: amarker of paclitaxel sensitivity in breast cancer. ProcNatl Acad Sci USA. 2005;102:8315−8318.30. Tsao MS et al: Erlotinib in lung cancer – molecu−lar and clinical predictors of outcome. N Engl J Med.2005;353:133−144.31. Miller VA et al: Molecular characteristics of bronchioal−veolar carcinoma and adenocarcinoma bronchioalveo−lar carcinoma subtype, predict response to erlotinibe. JClin Oncol. 2008:26:1472−1478.32. Sequist LV et al: First−line gefinitib in patients with ad−vanced non−small−cell lung cancer harboring somaticEGFR mutations. J Clin Oncol. 2008:26:2442−2449.33. Simon GR et al: ERCC1 expression as a predictor ofsurvival in resected patients with non−small cell lungcancer. Chest. 2005; 127:978−983.34. Lord RV et al: Low ERCC1 expression correlates withprolonged survival after cisplatin plus gemcitabinechemotherapy in non−small cell lung cancer. Clin can−cer Res. 2002;8:2286−2291.35. Olaussen KA et al: DNA repair by ERCC1 in non−small−cell lung cancer and cisplatin−based adjuvant chemo−therapy. N Engl J Med. 2006;355:983−991.36. Slebos RJ et al: K−ras oncogene activation as a prog−nostic marker in adenocarcinoma of the lung. N Engl JMed. 1990; 323:561−565.37. Eberhard DA et al. Mutations in the epidermal growthfactor receptor and in KRAS are predictive and prog−nostic indicators in patients with non−small−cell lungcancer treated with chemotherapy alone and in combi−nation with erlotinib. J Clin Oncol. 2005;23:5900−5909.38. Tsao MS et al: Prognostic and predictive importance ofp53 and RAS for adjuvant chemotherapy in non−small−cell lung cancer. J Clin Oncol. 2007;25:5240−5247.39. Marchetti et al: EGFR mutations in non−small−cell lungcancer: Analysis of a large series of cases and devel−opment of a rapid and sensitive method for diagnosticscreening with potential implications on pharmaco−logic treatment, J Clin Oncol. 2005;23:857−865.40. Bepler G et al: RRM1 and PTEN as prognostic pa−rameters for overall and disease−free survival in pa−tients with non−small−cell lung cancer. J Clin Oncol.2004;22:1878−1885.41. Zheng et al: DNA synthesis and repair genes RRM1and ERCC1 in lung cancer. N Engl J Med. 2007;356:800−808.